Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.42 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735099 | 0.85 | HDAC8 (0.56) | HDAC8GPR139KAT6ATAS1R3TAS1R1 | |
| SCHEMBL25213964 | 0.82 | HDAC8 (0.57) | HDAC8GPR139KAT6ATAS1R3TAS1R1 | |
| SCHEMBL14319078 | 0.82 | CES2 (0.59) | TAS1R3TAS1R1SMN1; SMN2SLC6A2 | |
| SCHEMBL13035442 | 0.82 | HDAC4 (0.49) | HDAC8LMNASMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL20812217 | 0.81 | HDAC8 (0.53) | HDAC8GPR139KAT6ATAS1R3TAS1R1 | |
| SCHEMBL1557170 | 0.81 | HDAC8 (0.53) | HDAC8GPR139KAT6ATAS1R3TAS1R1 | |
| SCHEMBL14099677 | 0.79 | HDAC8 (0.56) | HDAC8GPR139KAT6ATAS1R3TAS1R1 | |
| SCHEMBL9100679 | 0.78 | HDAC8 (0.48) | HDAC8 | |
| SCHEMBL9100669 | 0.78 | HDAC8 (0.48) | HDAC8 | |
| SCHEMBL13412203 | 0.78 | NPSR1 (0.57) | TAS1R3TAS1R1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671073-B2 | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671073-B2 | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-31 | — | — | US | disclosed |
| WO-2005116029-A1 | CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HDAC8 3101/4885GPR139 3266/4885KAT6A 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.